Commercial-stage biopharmaceutical company Precigen Inc (Nasdaq:PGEN) and the Recurrent Respiratory Papillomatosis Foundation (RRPF) announced on Thursday their continued collaboration in recognition of the third annual International RRP Awareness Day.

RRP is a rare, chronic, and debilitating disease caused by chronic human papillomavirus (HPV) 6 or 11 infection leading to the growth of recurring benign tumours in the respiratory tract. It can significantly affect a person's voice, breathing, daily life, relationships and sense of normalcy.

For many patients, the disease has meant years of repeated surgical procedures and the challenge of living with a condition that remains poorly understood by the broader public. RRP affects both children and adults, with an estimated 27,000 adults in the United States and more than 170,000 adults worldwide living with the disease.

This year's RRP Awareness Day focuses on voices of the RRP community, highlighting experiences from patients, caregivers, families, and healthcare providers affected by the disease. A campaign hub at rrpawareness.org features community quotes, videos, and reflections that underscore the daily realities of RRP and the continued need for greater awareness.

In August 2025, the US Food and Drug Administration approved Precigen's HPV-specific immunotherapy for adults with RRP, claimed to be the first and only approved therapy for RRP.